Inmune Bio (INMB)
NASDAQ:INMB
Top Page
Inmune Bio
(NASDAQ:INMB)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.50
▼(-1.96% Downside)
Action:UpgradedDate:01/28/26
Score is held back primarily by weak financial performance (large losses and sustained cash burn). The latest earnings call provides a meaningful offset via improved quarterly loss profile, stated cash runway into late 2026, and defined regulatory milestones, while technicals are mixed and valuation is constrained by negative earnings and no dividend.
Positive Factors
Platform Pipeline Diversification
INmune’s portfolio spans a cell therapy (CORDStrom), an allogeneic NK-cell program (INKmune) and a TNF-targeting biologic (XPro). Multiple distinct modalities and indications reduce single-program binary risk and create multiple regulatory and commercialization pathways over the next 2–4 years.
Negative Factors
Sustained Cash Burn and Negative Free Cash Flow
Persistent negative operating and free cash flow indicates the company consumes substantial cash to fund development. Over multiple quarters this necessitates external financing, increases dilution risk, and constrains strategic optionality unless revenue or funding sources change materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform Pipeline Diversification
INmune’s portfolio spans a cell therapy (CORDStrom), an allogeneic NK-cell program (INKmune) and a TNF-targeting biologic (XPro). Multiple distinct modalities and indications reduce single-program binary risk and create multiple regulatory and commercialization pathways over the next 2–4 years.
Read all positive factors
Inmune Bio (INMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.90M
Dividend YieldN/A
Average Volume (3M)527.96K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue Growth19.05%
EPS Growth2.01%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding26,585,258
10 Day Avg. Volume585,631
30 Day Avg. Volume527,962
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.90
Price to Sales (P/S)6652.75
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue104.97
Enterprise Value/Gross Profit238.56
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$8.50Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.99
Revenue Forecast (FY)N/A
Inmune Bio Business Overview & Revenue Model
Company Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, s...
How the Company Makes Money
Inmune Bio primarily generates revenue through strategic partnerships, licensing agreements, and potential future sales of its proprietary therapies upon approval. The company may receive upfront payments, milestone payments, and royalties from it...
Inmune Bio Earnings Call Summary
Earnings Call Date:Oct 30, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 30, 2026
Earnings Call Sentiment Positive
The earnings call reflected a generally positive sentiment with significant advancements in CORDStrom and INKmune platforms, as well as promising regulatory pathways for XPro. Financial results showed improved operating efficiency, although challenges with XPro trial results and regulatory delays were noted.Positive Updates
CORDStrom Advances Towards Regulatory Approval
CORDStrom is being prepared for submission for marketing approval in the U.K. and the U.S., showing significant improvements in patients with recessive dystrophic epidermolysis bullosa (RDEB), particularly in reducing itch and improving quality of life.
Negative Updates
Challenges with XPro Trial Results
Despite efforts, the company missed the top line on the MINDFuL trial for XPro, although they remain optimistic about its potential.
Read all updates
Q3-2025 Updates
Positive
Negative
CORDStrom Advances Towards Regulatory Approval
CORDStrom is being prepared for submission for marketing approval in the U.K. and the U.S., showing significant improvements in patients with recessive dystrophic epidermolysis bullosa (RDEB), particularly in reducing itch and improving quality of life.
Read all positive updates
Company Guidance
During INmune Bio's third quarter 2025 earnings call, the company provided several key guidance metrics. They reported a net loss of approximately $6.5 million, a significant improvement from the $12.1 million loss in the same period of 2024. Research and development expenses were $4.9 million, down from $10.1 million in the previous year. General and administrative expenses slightly increased to $2.5 million from $2.2 million. As of September 30, 2025, the company held $27.7 million in cash and cash equivalents, which they project will fund operations into Q4 2026. INmune Bio is focused on advancing their platform programs, notably planning to file a marketing authorization application (MAA) for CORDStrom in the UK by mid-2026 and subsequently a biologics licensing application (BLA) in the US. They are also pursuing an accelerated regulatory pathway for their XPro platform in Alzheimer's treatment and expect regulatory alignment with the FDA by Q1 2026.Inmune Bio Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
52
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.00K | 14.00K | 155.00K | 374.00K | 181.00K | 11.00K |
| Gross Profit | 22.00K | 14.00K | 155.00K | 374.00K | 181.00K | 11.00K |
| EBITDA | -33.62M | -42.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -49.89M | -42.08M | -30.01M | -27.30M | -30.34M | -12.10M |
Balance Sheet | ||||||
| Total Assets | 33.36M | 39.56M | 57.00M | 81.80M | 99.94M | 40.66M |
| Cash, Cash Equivalents and Short-Term Investments | 27.73M | 20.92M | 35.85M | 52.15M | 74.81M | 21.97M |
| Total Debt | 1.08M | 384.00K | 10.44M | 15.31M | 15.23M | 160.00K |
| Total Liabilities | 7.98M | 7.46M | 18.86M | 21.69M | 19.72M | 1.90M |
| Stockholders Equity | 25.38M | 32.10M | 38.14M | 60.10M | 80.22M | 38.75M |
Cash Flow | ||||||
| Free Cash Flow | -31.55M | -33.36M | -11.98M | -22.69M | -43.50M | -8.94M |
| Operating Cash Flow | -30.65M | -33.36M | -11.98M | -22.69M | -28.50M | -8.94M |
| Investing Cash Flow | -899.00K | 0.00 | 0.00 | 0.00 | -15.00M | 0.00 |
| Financing Cash Flow | 25.47M | 18.21M | -4.22M | 729.00K | 96.36M | 23.90M |
Inmune Bio Technical Analysis
Negative
1.53
Price Trends
1.43
Negative
1.56
Negative
2.22
Negative
Market Momentum
-0.06
Positive
42.91
Neutral
22.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INMB, the sentiment is Negative. The current price of 1.53 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.43, and below the 200-day MA of 2.22, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 42.91 is Neutral, neither overbought nor oversold. The STOCH value of 22.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INMB.
Inmune Bio Risk Analysis
Inmune Bio disclosed 59 risk factors in its most recent earnings report. Inmune Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inmune Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $31.90M | -2.13 | -172.00% | ― | 19.05% | 2.01% | |
46 Neutral | $35.79M | -2.04 | -83.24% | ― | -100.00% | 55.10% | |
46 Neutral | $102.18M | -0.41 | 77.87% | ― | -3.98% | -29.94% | |
45 Neutral | $24.50M | 5.20 | -271.67% | ― | -25.51% | 49.72% | |
44 Neutral | $34.61M | -0.59 | 763.31% | ― | -15.81% | -113.06% |
* Healthcare Sector Average
INMB
Inmune Bio
1.20
-6.21
-83.81%
VERU
Veru
2.23
-3.25
-59.31%
KPTI
Karyopharm Therapeutics
5.57
1.22
28.05%
CUE
Cue Biopharma
0.25
-0.75
-75.00%
CELU
Celularity
1.20
-0.68
-36.17%
JUNS
Jupiter Neurosciences, Inc.
0.35
-0.39
-52.84%
Inmune Bio Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
INmune Bio outlines 2026 regulatory path in shareholder letter
Positive
Jan 27, 2026
In a shareholder letter dated January 27, 2026, INmune Bio reviewed 2025 as a pivotal year marked by progress in two lead programs and solidified financial footing. The company reported substantial advances in CORDStrom™ for RDEB, including ...
Business Operations and StrategyPrivate Placements and Financing
Inmune Bio Amends April 2024 Investor Warrants
Positive
Dec 23, 2025
On December 22, 2025, INmune Bio Inc. amended certain investor warrants issued in its April 24 and April 29, 2024 offerings, adjusting the terms on 1,348,315 outstanding warrants. The company reduced the exercise price of these April 2024 warrants...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
INmune Bio Establishes $65 Million At-The-Market Offering
Neutral
Dec 19, 2025
On December 19, 2025, INmune Bio Inc. entered into a sales agreement with A.G.P./Alliance Global Partners, allowing the company to sell up to $65 million of its common stock from time to time through at-the-market offerings under an existing shelf...
Business Operations and StrategyPrivate Placements and Financing
Inmune Bio Ends Sales Agreement with RBC and BTIG
Neutral
Dec 10, 2025
INmune Bio Inc. announced the termination of its Amended and Restated At-The-Market Sales Agreement with RBC Capital Markets, LLC and BTIG, LLC, effective December 19, 2025. The company had previously raised approximately $10.5 million through the...
Business Operations and StrategyProduct-Related Announcements
Inmune Bio Unveils Promising Alzheimer’s Trial Data
Positive
Dec 5, 2025
On December 1, 2025, INmune Bio Inc. announced new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595, presented at the Clinical Trials on Alzheimer’s Disease conference. The data, which showed a trend towards slowed neurodegenerat...
Executive/Board Changes
Inmune Bio Updates Executive Employment Agreements
Neutral
Dec 3, 2025
On December 2, 2025, INmune Bio Inc. announced amendments to the employment agreements of its President and Chief Executive, David J. Moss, and its Chief Financial Officer, Cory Ellspermann. The amendments corrected errors in the original agreemen...
Executive/Board Changes
Inmune Bio Announces New Executive Employment Agreements
Neutral
Nov 28, 2025
On November 26, 2025, INmune Bio Inc. announced new employment agreements for key executives, effective November 1, 2025. David J. Moss, President and CEO, will receive a base salary of $500,000, a discretionary bonus, and stock options, with prov...
Business Operations and StrategyShareholder Meetings
INmune Bio Approves Option Repricing Proposal
Neutral
Nov 18, 2025
On November 18, 2025, INmune Bio held a virtual special meeting of stockholders where the Option Repricing Proposal was approved. The company also announced its participation in the 18th Clinical Trials on Alzheimer’s Disease conference in D...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Inmune Bio Advances Immunotherapy Pipeline with Phase 2 Completion
Positive
Nov 10, 2025
INmune Bio Inc. has prepared a presentation slide deck to be used in future presentations, highlighting their progress in developing immunotherapies. The company is advancing its late-stage pipeline with key programs like CORDStrom and XPro, targe...
Business Operations and StrategyFinancial Disclosures
Inmune Bio to Host Q3 Results Conference Call
Neutral
Oct 28, 2025
On October 23, 2025, INmune Bio Inc. announced it will host a conference call on October 30, 2025, to discuss its third-quarter financial results and provide a corporate update. This event is significant for stakeholders as it will offer insights ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.